A case of advanced bladder neuroendocrine carcinoma (Small cell carcinoma) significantly improved by low dose of oral tegafur-uracil

Hayahito Nomi, Kiyoshi Takahara, Koichiro Minami, Ryoichi Maenosono, Tomohisa Matsunaga, Yuki Yoshikawa, Takuya Tsujino, Hajime Hirano, Teruo Inamoto, Ikuhisa Yamamoto, Motomu Tsuji, Satoshi Kiyama, Haruhito Azuma

Research output: Contribution to journalArticle

Abstract

A 81-old-woman underwent a transurethral resection of bladder tumor (TURBT) at a nearby hospital in April 2011. The diagnosis was invasive urothelial carcinoma, G3 with a component of bladder small cell carcinoma, Tl or more. She was recommended to visit our hospital for combined modality therapy of bladder cancer, but she refused the treatment for over one year. In May 2012, she came to our hospital with the chief complaint of pain at urination. Cystoscopy revealed non-papillary sessile tumor in the top of the bladder, and CT scan demonstrated the presence of the right obturator lymph nodes swollen up to 1.2 cm in size. The second TURBT was performed and the diagnosis was bladder small cell carcinoma (pT3N2M0) according to urothelial cancer guidelines of the Japanese Urological Association (JUA). Because she strongly refused hospitalization anymore, we started daily oral intake of low dose Tegafur-Uracil (100 mg) for the treatment. After one month, the serum Neuron-Specific Enolase (NSE; tumor maker of small cell cancer) level was elevated to 27.6 ng/ml and the right obturator lymph node was enlarged up to 1.9 cm. Therefore, the Trgafur-Uracil dose was increased to 200 mg daily. After then, the serum NSE level was decreased to 15.5 ng/ml following reduction in size of the obturator lymph nodes with partial response in December 2013. After two years of follow-up period, her regular urine test showed normal findings, and no apparent recurrence was detected on urinary bladder with MRI and Cystoscopy. This is a case of advanced bladder small cell carcinoma significantly improved by oral administration of Tegafur-Uracil 200 mg/day for over 2 years.

Original languageEnglish
Pages (from-to)269-273
Number of pages5
JournalJapanese Journal of Urology
Volume106
Issue number4
DOIs
Publication statusPublished - 01-10-2015
Externally publishedYes

Fingerprint

Tegafur
Neuroendocrine Carcinoma
Small Cell Carcinoma
Uracil
Urinary Bladder
Urinary Bladder Neoplasms
Cystoscopy
Lymph Nodes
Neoplasms
Combined Modality Therapy
Phosphopyruvate Hydratase
Urination
Serum
Oral Administration
Hospitalization
Urine
Guidelines
Carcinoma
Recurrence
Pain

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Nomi, Hayahito ; Takahara, Kiyoshi ; Minami, Koichiro ; Maenosono, Ryoichi ; Matsunaga, Tomohisa ; Yoshikawa, Yuki ; Tsujino, Takuya ; Hirano, Hajime ; Inamoto, Teruo ; Yamamoto, Ikuhisa ; Tsuji, Motomu ; Kiyama, Satoshi ; Azuma, Haruhito. / A case of advanced bladder neuroendocrine carcinoma (Small cell carcinoma) significantly improved by low dose of oral tegafur-uracil. In: Japanese Journal of Urology. 2015 ; Vol. 106, No. 4. pp. 269-273.
@article{1d7a9f6472bd40588a22f595287d1229,
title = "A case of advanced bladder neuroendocrine carcinoma (Small cell carcinoma) significantly improved by low dose of oral tegafur-uracil",
abstract = "A 81-old-woman underwent a transurethral resection of bladder tumor (TURBT) at a nearby hospital in April 2011. The diagnosis was invasive urothelial carcinoma, G3 with a component of bladder small cell carcinoma, Tl or more. She was recommended to visit our hospital for combined modality therapy of bladder cancer, but she refused the treatment for over one year. In May 2012, she came to our hospital with the chief complaint of pain at urination. Cystoscopy revealed non-papillary sessile tumor in the top of the bladder, and CT scan demonstrated the presence of the right obturator lymph nodes swollen up to 1.2 cm in size. The second TURBT was performed and the diagnosis was bladder small cell carcinoma (pT3N2M0) according to urothelial cancer guidelines of the Japanese Urological Association (JUA). Because she strongly refused hospitalization anymore, we started daily oral intake of low dose Tegafur-Uracil (100 mg) for the treatment. After one month, the serum Neuron-Specific Enolase (NSE; tumor maker of small cell cancer) level was elevated to 27.6 ng/ml and the right obturator lymph node was enlarged up to 1.9 cm. Therefore, the Trgafur-Uracil dose was increased to 200 mg daily. After then, the serum NSE level was decreased to 15.5 ng/ml following reduction in size of the obturator lymph nodes with partial response in December 2013. After two years of follow-up period, her regular urine test showed normal findings, and no apparent recurrence was detected on urinary bladder with MRI and Cystoscopy. This is a case of advanced bladder small cell carcinoma significantly improved by oral administration of Tegafur-Uracil 200 mg/day for over 2 years.",
author = "Hayahito Nomi and Kiyoshi Takahara and Koichiro Minami and Ryoichi Maenosono and Tomohisa Matsunaga and Yuki Yoshikawa and Takuya Tsujino and Hajime Hirano and Teruo Inamoto and Ikuhisa Yamamoto and Motomu Tsuji and Satoshi Kiyama and Haruhito Azuma",
year = "2015",
month = "10",
day = "1",
doi = "10.5980/jpnjurol.106.269",
language = "English",
volume = "106",
pages = "269--273",
journal = "Japanese Journal of Urology",
issn = "0021-5287",
publisher = "Japanese Urological Association",
number = "4",

}

Nomi, H, Takahara, K, Minami, K, Maenosono, R, Matsunaga, T, Yoshikawa, Y, Tsujino, T, Hirano, H, Inamoto, T, Yamamoto, I, Tsuji, M, Kiyama, S & Azuma, H 2015, 'A case of advanced bladder neuroendocrine carcinoma (Small cell carcinoma) significantly improved by low dose of oral tegafur-uracil', Japanese Journal of Urology, vol. 106, no. 4, pp. 269-273. https://doi.org/10.5980/jpnjurol.106.269

A case of advanced bladder neuroendocrine carcinoma (Small cell carcinoma) significantly improved by low dose of oral tegafur-uracil. / Nomi, Hayahito; Takahara, Kiyoshi; Minami, Koichiro; Maenosono, Ryoichi; Matsunaga, Tomohisa; Yoshikawa, Yuki; Tsujino, Takuya; Hirano, Hajime; Inamoto, Teruo; Yamamoto, Ikuhisa; Tsuji, Motomu; Kiyama, Satoshi; Azuma, Haruhito.

In: Japanese Journal of Urology, Vol. 106, No. 4, 01.10.2015, p. 269-273.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case of advanced bladder neuroendocrine carcinoma (Small cell carcinoma) significantly improved by low dose of oral tegafur-uracil

AU - Nomi, Hayahito

AU - Takahara, Kiyoshi

AU - Minami, Koichiro

AU - Maenosono, Ryoichi

AU - Matsunaga, Tomohisa

AU - Yoshikawa, Yuki

AU - Tsujino, Takuya

AU - Hirano, Hajime

AU - Inamoto, Teruo

AU - Yamamoto, Ikuhisa

AU - Tsuji, Motomu

AU - Kiyama, Satoshi

AU - Azuma, Haruhito

PY - 2015/10/1

Y1 - 2015/10/1

N2 - A 81-old-woman underwent a transurethral resection of bladder tumor (TURBT) at a nearby hospital in April 2011. The diagnosis was invasive urothelial carcinoma, G3 with a component of bladder small cell carcinoma, Tl or more. She was recommended to visit our hospital for combined modality therapy of bladder cancer, but she refused the treatment for over one year. In May 2012, she came to our hospital with the chief complaint of pain at urination. Cystoscopy revealed non-papillary sessile tumor in the top of the bladder, and CT scan demonstrated the presence of the right obturator lymph nodes swollen up to 1.2 cm in size. The second TURBT was performed and the diagnosis was bladder small cell carcinoma (pT3N2M0) according to urothelial cancer guidelines of the Japanese Urological Association (JUA). Because she strongly refused hospitalization anymore, we started daily oral intake of low dose Tegafur-Uracil (100 mg) for the treatment. After one month, the serum Neuron-Specific Enolase (NSE; tumor maker of small cell cancer) level was elevated to 27.6 ng/ml and the right obturator lymph node was enlarged up to 1.9 cm. Therefore, the Trgafur-Uracil dose was increased to 200 mg daily. After then, the serum NSE level was decreased to 15.5 ng/ml following reduction in size of the obturator lymph nodes with partial response in December 2013. After two years of follow-up period, her regular urine test showed normal findings, and no apparent recurrence was detected on urinary bladder with MRI and Cystoscopy. This is a case of advanced bladder small cell carcinoma significantly improved by oral administration of Tegafur-Uracil 200 mg/day for over 2 years.

AB - A 81-old-woman underwent a transurethral resection of bladder tumor (TURBT) at a nearby hospital in April 2011. The diagnosis was invasive urothelial carcinoma, G3 with a component of bladder small cell carcinoma, Tl or more. She was recommended to visit our hospital for combined modality therapy of bladder cancer, but she refused the treatment for over one year. In May 2012, she came to our hospital with the chief complaint of pain at urination. Cystoscopy revealed non-papillary sessile tumor in the top of the bladder, and CT scan demonstrated the presence of the right obturator lymph nodes swollen up to 1.2 cm in size. The second TURBT was performed and the diagnosis was bladder small cell carcinoma (pT3N2M0) according to urothelial cancer guidelines of the Japanese Urological Association (JUA). Because she strongly refused hospitalization anymore, we started daily oral intake of low dose Tegafur-Uracil (100 mg) for the treatment. After one month, the serum Neuron-Specific Enolase (NSE; tumor maker of small cell cancer) level was elevated to 27.6 ng/ml and the right obturator lymph node was enlarged up to 1.9 cm. Therefore, the Trgafur-Uracil dose was increased to 200 mg daily. After then, the serum NSE level was decreased to 15.5 ng/ml following reduction in size of the obturator lymph nodes with partial response in December 2013. After two years of follow-up period, her regular urine test showed normal findings, and no apparent recurrence was detected on urinary bladder with MRI and Cystoscopy. This is a case of advanced bladder small cell carcinoma significantly improved by oral administration of Tegafur-Uracil 200 mg/day for over 2 years.

UR - http://www.scopus.com/inward/record.url?scp=84948686082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948686082&partnerID=8YFLogxK

U2 - 10.5980/jpnjurol.106.269

DO - 10.5980/jpnjurol.106.269

M3 - Article

VL - 106

SP - 269

EP - 273

JO - Japanese Journal of Urology

JF - Japanese Journal of Urology

SN - 0021-5287

IS - 4

ER -